Abstract
Objective
Many cancer patients continue to smoke post diagnosis, yet there have been few smoking cessation trials for this population. Depression, which is prevalent among cancer patients, may be a barrier to cessation.
Methods
This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7-day point-prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.
Results
There was no main effect of bupropion vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38–4.81, p = .64). Patients with depression symptoms reported significantly lower abstinence rates vs. patients without depression symptoms (OR = .14, 95% CI: 0.02–0.80, p = .03). Bupropion increased abstinence rates, vs. placebo, more for participants with depression vs. those without depression symptoms. For patients with depression symptoms, bupropion reduced withdrawal symptoms and improved quality of life vs. placebo.
Conclusions
For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with bupropion or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients.
Similar content being viewed by others
References
Videtic GM, Stitt LW, Dar AR et al (2003) Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncl 21:1544–1549
Schnoll RA, James C, Malstrom M et al (2003) Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med 25:214–222
Walker MS, Vidrine DJ, Gritz ER et al (2006) Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev 15:2370–2377
Zhou W, Heist RS, Liu G et al (2006) Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer 53:375–380
Garces YI, Schroeder DR, Nirelli LM et al (2007) Second primary tumors following tobacco dependence treatments among head and neck cancer patients. Am J Clin Oncol 30:531–539
Browman GP, Mohide EA, Willan A et al (2002) Association between smoking during radiotherapy and prognosis in head and neck cancer: a follow-up study. Head Neck 24:1031–1037
Carter CL, Key J, Marsh L et al (2001) Contemporary perspectives in tobacco cessation: what oncologists need to know. Oncologist 6:496–505
Tsao As, Liu D, Lee JJ, Sptiz M, Hong WK (2006) Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106:2428–2436
Rades D, Setter C, Schild SE, Dunst J (2008) Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 71:1134–1142
Vander Ark W, DiNardo LJ, Oliver DS (1997) Factors affecting smoking cessation in patients with head and neck cancer. Laryngoscope 107:888–892
Duarte RL, Luiz RR, Paschoal ME (2008) The cigarette burden (measured by the number of pack years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients. Lung Cancer 61:244–254
Baser S, Shannon VR, Eapen GA et al (2006) Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 130:1784–1790
Gritz ER, Fingeret MC, Vidrine DJ et al (2006) Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 106:17–27
Gritz ER, Vidrine DJ, Fingeret MC (2007) Smoking cessation a critical component of medical management in chronic disease populations. Am J Prev Med 33:S414–S422
Gritz ER, Carr CR, Rapkin D et al (1993) Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 2:261–270
Schnoll RA, Zhang B, Rue M et al (2003) Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 21:355–365
Schnoll RA, Rothman RL, Wielt DB et al (2005) A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. Ann Behav Med 30:1–11
Schnoll RA, Malstrom M, James C et al (2002) Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns 46:137–145
Covey LS, Glassman AH, Stetner F (1990) Depression and depressive symptoms in smoking cessation. Compr Psychiatry 31:350–354
Hayford KE, Patten CA, Rummans TA et al (1999) Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 174:173–178
Hughes JR (1992) Tobacco withdrawal in self-quitters. J Consult Clin Psychol 60:689–697
Pirl WF (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr 32:32–39
van Wilgen CP, Dijkstra PU, Stewart RE et al (2006) Measuring somatic symptoms with the CES-D to assess depression in cancer patients after treatment: comparison among patients with oral/oropharyngeal, gynecological, colorectal, and breast cancer. Psychosomatics 47:465–470
Lerman C, Roth D, Kaufmann V et al (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67:219–223
Catley D, Harris KJ, Okuyemi KS et al (2005) The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. Nicotine Tob Res 7:859–870
Hitsman B, Pingitore R, Spring B et al (1999) Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol 67:547–554
Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33
Martinez E, Tatum KL, Weber DM, et al (2009) Issues related to implementing a smoking cessation clinical trial for cancer patients. Cancer Causes Control 20:97–104
Radloff L (1977) The CES-D scale: a new self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401
Heatherton TF, Kozlowski LT, Frecker RC et al (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119–1127
de Graeff A, de Leeuw JR, Ros WJ et al (2000) Pretreatment factors predicting quality of life after treatment for head and neck cancer. Head Neck 22:398–407
Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063–1070
Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289–294
Heil SH, Higgins ST, Mongeon JA et al (2006) Characterizing nicotine withdrawal in pregnant cigarette smokers. Exp Clin Psychopharmacol 14:165–170
Brown R, Burgess E, Sales S et al (1998) Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav 12:101–112
Ware J Jr, Kosinski M, Keller SD (1996) A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233
McCorkle R, Dowd M, Ercolano E, et al (2009) Effects of a nursing intervention on quality of life outcomes in post-surgical women with gynecological cancers. Psychooncology 18:62–70
Gandek B, Ware JE, Aaronson NK et al (1998) Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51:1171–1178
Fiore MC, Jaén CR, Baker TB, et al (2008) Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, May 2008
Glaxo_Wellcome (1999) Bupropion hydrochloride sustained-release tablets prescribing information. Research Triangle Park, North Carolina, USA
Holm KJ, Spencer CM (2000) Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007–1024
Jorenby DE, Leischow SJ, Nides MA et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691
Cox LS, Patten CA, Niaura RS et al (2004) Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 19:828–834
Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev: CD000031
Rigotti NA, Munafo MR, Stead LF (2007) Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev: CD001837
Rigotti NA, Munafo MR, Stead LF (2008) Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 168:1950–1960
Shiffman S, Johnston JA, Khayrallah M et al (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33–40
Piper ME, Federmen EB, McCarthy DE et al (2008) Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol 117:94–105
Teneggi V, Tiffany ST, Squassante L et al (2005) Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology 183:1–12
Schnoll RA, Rothman RL, Lerman C et al (2004) Comparing cancer patients who enroll in a smoking cessation program at a Comprehensive Cancer Center with those who decline. Head Neck 26:278–286
Gonzales D, Rennard SI, Nides M et al (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55
Dy SM, Lorenz KA, Naeim A et al (2008) Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26:2886–2895
Acknowledgments
The authors would like to thank Ms. Jeanne Pomenti for assisting with the preparation of this manuscript. This study was funded by grant R01 CA95678 from the National Cancer Institute. Transdermal nicotine patches were provided free-of-charge by GlaxoSmithKline. All sites provided Institutional Review Board approval. All patients provided informed consent for this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schnoll, R.A., Martinez, E., Tatum, K.L. et al. A bupropion smoking cessation clinical trial for cancer patients. Cancer Causes Control 21, 811–820 (2010). https://doi.org/10.1007/s10552-010-9507-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-010-9507-8